Table 1.
Cell culture
|
Immunohistochemistry
|
|||
---|---|---|---|---|
Sample ID | Diagnosis | Sample ID | Cycle phase | Diagnosis |
298 | No endo (P) | 441 | PE | No endo (Fb, M) |
316 | No endo (P, A, Fb) | 426 | PE | No endo (Dm, Dp, M) |
229 | No endo (PP) | 539 | PE | No endo (Fb) |
236 | No endo (POP) | 588 | PE | Endo, stage II |
275 | No endo (Fb) | 634 | PE | Endo, stage II |
277 | No endo (Fb) | 697 | PE | Endo, stage IV |
285 | No endo (Fb) | 114 | PE | Endo, stage IV |
293 | No endo (Fb) | 123 | PE | Endo, stage IV |
326 | No endo (Fb) | |||
310 | No endo (Fb, Ec) | 650 | ES | No endo (Fb, M) |
456 | ES | No endo (Fb, Dm, Mm) | ||
233 | Endo, stage II | 458 | ES | No endo (M) |
272 | Endo, stage II–IV (A) | 680 | ES | No endo (UVP) |
242 | Endo, stage I–II | 24 | ES | No endo (M) |
243 | Endo, stage II–III (A, Fb) | 607 | ES | Endo, stage IV |
279 | Endo, stage II–IV | 599 | ES | Endo, stage IV |
288 | Endo, stage IV | 591 | ES | Endo, stage I |
307 | Endo, stage IV | 625 | ES | Endo, unstaged |
314 | Endo, stage IV | 471 | ES | Endo, stage III–IV |
375 | Endo, stage IV | 127 | ES | Endo, stage IV |
381 | Endo, stage IV | |||
271 | Endo, stage IV (A) | 626 | MS | No endo (Cc, Rc) |
305 | Endo, stage IV (Fb) | 465 | MS | No endo (Fb) |
665 | MS | No endo (Fb, M, PP, A) | ||
635 | MS | Endo, stage II | ||
546 | MS | Endo, stage II (A) | ||
37 | MS | Endo, stage III | ||
526 | MS | Endo, stage III–IV (A) | ||
462 | LS | No endo (SUI) | ||
614 | LS | No endo (UVP) | ||
648 | LS | No endo (Fb, SUI) | ||
576 | LS | No endo (POC) |
A, Adenomyosis; Cc, cystocele; Dm, dysmenorrhea; Dp, dysparenuria; Ec, enterocele; Endo, endometriosis; Fb, uterine fibroids; M, menorrhagia; Mm, menometrorrhagia; No endo, without endometriosis; P, polyp; POC, paratubal ovarian cyst; POP, pelvic organ prolapse; PP, pelvic pain; Rc, rectocele; SUI, stress urinary incontinence; UVP, uterovaginal prolapse.